Every 10-Q that Artivion, Inc. (AORT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AORT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AORT filings page.
Artivion, Inc. reported stronger top-line results but weaker profitability for the quarter ended June 30, 2026. Total revenues grew 11% year over year to $125,757 thousand, and six‑month revenues rose 14% to $242,094 thousand, driven mainly by aortic stent grafts and On‑X mechanical heart valves. Aortic stent graft revenues increased 16% in the quarter and 19% year to date, while On‑X products rose 19% and 20%, respectively.
Despite higher gross margin dollars, Artivion posted an operating loss of $8,364 thousand versus prior‑year operating income of $8,384 thousand, and a quarterly net loss of $13,510 thousand compared with net income of $1,345 thousand. Results were pressured by higher general, administrative, and marketing expenses, increased research and development spending, acquisition‑related costs of $12,500 thousand tied to the Endospan transaction, and a $9,710 thousand increase in fair value of contingent consideration related to Ascyrus. Interest expense remained elevated at $7,253 thousand for the quarter.
Artivion closed the Endospan acquisition with total consideration fair value of $178,062 thousand, adding $99,206 thousand of goodwill and $71,800 thousand of identifiable intangibles, and recognized new contingent consideration of $26,227 thousand. Separately, FDA Premarket Approval of the AMDS Hybrid Prosthesis in June 2026 triggered a $25,000 thousand milestone payment and raised AMDS‑related contingent liabilities to $70,290 thousand. To fund growth, total principal debt increased to $370,000 thousand, including a full draw of the $150,000 thousand delayed‑draw term loan, while cash and cash equivalents rose to $77,316 thousand. Operating cash flow was near breakeven for the first half. The company also disclosed an ongoing German tax examination with potential additional exposure of about €7 million if the tax authority’s position prevails, but recorded no adjustment based on its current ASC 740 assessment.
Artivion, Inc. reported strong quarterly growth, with revenues for the three months ended March 31, 2026 rising 18% to $116.3 million and net income improving to $1.4 million from a prior-year loss. Growth was driven by higher sales of aortic stent grafts, On‑X heart valves, surgical sealants, and preservation services, plus favorable foreign exchange.
Gross margin increased to $75.4 million, or 65% of revenue, helped by a richer product mix and higher pricing. Operating income more than doubled to $5.8 million as revenue growth outpaced higher spending on sales, marketing, and research and development.
Artivion ended the quarter with $55.8 million in cash and $220.0 million of principal debt outstanding, and generated positive operating cash flow of $1.2 million. The company exercised its option to acquire Endospan, planning to fund the $135.0 million upfront purchase price with a $150.0 million delayed draw term loan facility.
Artivion (AORT) reported third‑quarter 2025 results with total revenues of $113.4 million, up 18% year over year. Medical devices drove growth, led by aortic stent grafts $39.6 million (+38%) and On‑X $26.8 million (+25%), while preservation services contributed $25.7 million (+5%). Gross margin was $74.4 million, and operating income rose to $12.5 million.
Net income was $6.5 million (diluted EPS $0.13) versus a loss a year ago, aided by a $3.5 million PerClot sales milestone gain. Operating cash flow reached $20.3 million year to date, ending cash was $73.4 million. The company eliminated its $100.0 million Convertible Senior Notes via exchanges into ~4.35 million shares and small residual settlement, reducing interest expense. A credit amendment extended maturities to January 18, 2031 and lowered interest margins; total principal debt stood at $220.0 million with long‑term debt (net) of $214.9 million. Shares outstanding were 47,374,939 as of October 31, 2025.
Artivion (AORT) Q2-25 10-Q highlights
- Revenue rose 15% YoY to $113.0 m; product sales +19% (notably aortic stent grafts +24%, On-X valves +24%), while preservation services +3%.
- Profitability: Gross margin expanded to $73.1 m (64.7% of sales) vs $63.3 m. Operating income improved 29% to $8.4 m, but six-month operating income fell sharply to $10.5 m (vs $31.8 m) due to higher SG&A (+17%) and a $2.7 m debt-conversion inducement.
- Net income swung to $1.3 m (EPS $0.03) from a $2.1 m loss; YTD net income slipped to $0.8 m (EPS $0.02) vs $5.4 m.
- Cash flow: Operating cash outflow of $1.9 m vs $0.6 m inflow prior year; FCF negative $8.9 m after $6.9 m capex.
- Balance sheet: Long-term debt cut to $215.5 m from $314.2 m after exchanging $99.5 m of 4.25% convertible notes for 4.33 m shares. Total liabilities down $94 m; equity up to $419.9 m. Cash steady at $53.5 m.
- Liquidity & covenants: Company remains within leverage covenant (<6.25x); Term Loan ($190 m) carries 10.6% interest, Revolver drawn $30 m.
- Strategic moves: Amended Endospan option lowers potential acquisition price to $175 m and funds additional $25 m loans (FV $10.3 m). Adopted ASU 2024-04 for debt conversions. OBBBA tax law impact under evaluation.
Overall, Q2 shows solid top-line momentum and deleveraging, offset by weak cash generation, elevated interest costs and mixed preservation-service trends.